T1DM is an autoimmune disorder characterized by the destruction of beta cells, resulting in an absolute deficiency of insulin ...

MyndMed™’s formula, developed by BioAdaptives’ research team, incorporates a precise blend of botanical extracts, amino acids, and neuro-support nutrients designed to support neurotransmitter balance, ...

King Faisal Specialist Hospital and Research Centre (KFSHRC) delivered 293,381 virtual clinic visits in 2024, a 58.2% increase from the previous year. The growth highlights how telehealth has become ...

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, ...

Inspire is scheduled to present at 11:00 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following ...

Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in New York Links for live webcasts and replays, if available, will be available in the on the “Investors” ...

With the Newly Granted IP, the Company’s IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending. The Company Continues to Scale Commercial ...

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Boehringer Ingelheim for Hernexeos ® (Zongertinib). The Food and Drug Administration approved ...

Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that ...

NANTES, France - 20 août 2025, 18 h 00 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), annonce aujourd’hui la nomination de Thomas Gidoin au poste de Directeur Financier. Thomas rejoint ...

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will ...

Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen acted as joint book-running managers for the offering.